)
ALTEOGEN (196170) investor relations material
ALTEOGEN Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Operates in biopharmaceutical R&D, production, and sales, focusing on proprietary platform technologies for subcutaneous drug delivery and next-generation biologics.
Major revenue from licensing out core technologies (ALT-B4, biosimilars) to global pharma partners, with upfront, milestone, and royalty income.
Recent product launches and regulatory approvals in Korea, China, and Europe for biosimilars and proprietary drugs.
Financial highlights
2026 H1 consolidated revenue: ₩140.5B, down from ₩215.9B in 2025 H1.
Operating income: ₩73.5B (2025 H1: ₩106.9B); net income: ₩101.3B (2025 H1: ₩145.2B).
Gross margin remains strong; basic EPS for H1 2026: ₩1,871.
Cash and cash equivalents at period end: ₩80.4B.
Outlook and guidance
Expects continued stable cash inflow from existing and new licensing deals.
Ongoing expansion of product pipeline and global regulatory submissions for biosimilars and new biologics.
Plans to invest in commercial-scale manufacturing facilities.
- 2024 saw record profits and new global licensing deals, driving strong growth and liquidity.196170
Q4 2024 - H1 2024 net profit hit ₩17.7B, driven by global licensing and milestone payments.196170
Q2 2024 - Q3 2024 net income reached ₩8.3B, with strong licensing and R&D-driven growth.196170
Q3 2024 - Record Q1 2025 revenue and profit fueled by global licensing, product launches, and strong cash flow.196170
Q1 2025 - Record revenue and profit growth fueled by global licensing, robust cash flow, and pipeline expansion.196170
Q4 2025 - Record revenue and profit growth in 2025 Q3, fueled by licensing and global product approvals.196170
Q3 2025 - H1 2025 revenue and profit soared on licensing deals, with robust cash and pipeline growth.196170
Q2 2025 - Q1 2026 delivered high net income and major global licensing deals, supporting future growth.196170
Q1 2026 - Strong pipeline, global partnerships, and innovation fuel rapid revenue and product growth.196170
44th Annual J.P. Morgan Healthcare Conference Presentation
Next ALTEOGEN earnings date
Next ALTEOGEN earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage